$ALKS

Gaffin David Joseph sold $99K of ALKS

Gaffin David Joseph (EVP, CLO, Alkermes, Inc.) sold 2,034 shares of Alkermes plc. (ALKS) at $48.58 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gaffin David Joseph
Published Aug 3, 2026, 11:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 11:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ALKS
Neutral
high confidence
Mentioned
$ALKS
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

The only new information is the specific sale size, price, and post-transaction holdings; it does not provide new company performance or outlook data.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 structure and lack of fundamental updates make it low-impact.

03

What to watch

The filing does not include any accompanying corporate event (guidance, contract, trial, or restructuring), so traders should avoid over-interpreting it as a fundamental signal.

Relevance 2/10Novelty 3/10Timing: filed 2026-08-03 (same day as the sale)

Background

The article is a SEC Form 4 insider transaction for Alkermes plc, reported by an EVP and executed as an open-market sale under a 10b5-1 plan.

Company-level read

Ticker impact

$ALKSNeutralHigh confidence
Context

Alkermes disclosed an EVP open-market sale of 2,034 shares at $48.58 on 2026-08-03 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this filing alone; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

Form 4 shows a planned open-market transaction by an officer, not a new operational or financial disclosure.

Market effects

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or demand changes.

None indicated.

None indicated.

Counterpoint

Because it is explicitly under a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Alkermes plc

    Subject of the Form 4 insider transaction disclosure.

  • Gaffin David Joseph

    EVP, CLO at Alkermes, reported an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALKSMedAI 8/10

Phase 2 Data on Investigational Narcolepsy Drug Published

Alkermes' investigational narcolepsy drug alixorexton showed statistically significant improvements in wakefulness and cataplexy in a phase 2 study. The treatment was well-tolerated and improved patient-reported outcomes. The company has initiated a phase 3 program based on these results, according to the company.

$ALKSMedAI 9/10

Did Positive Vibrance-1 Data and Brilliance Phase 3 Launch Just Shift Alkermes' (ALKS) Investment Narrative?

Alkermes (ALKS) reported positive Phase 2 data for alixorexton in narcolepsy, leading to a global Phase 3 trial launch. The data, published in The Lancet Neurology, showed significant improvements in wakefulness and safety. The company aims for $2.3B revenue by 2029, with analysts projecting up to $2.8B. Success hinges on Phase 3 trial outcomes.

$ALKSMedAI 8/10

Alkermes plc: The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

Alkermes (ALKS) announced positive phase 2 study results for alixorexton in adults with narcolepsy type 1, published in The Lancet Neurology. The study showed statistically significant improvements in wakefulness and cataplexy, with all doses well-tolerated. Alkermes has initiated phase 3 trials for alixorexton in narcolepsy types 1 and 2.